TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17400660

Group type: EXPERIMENTAL
Intervention: HeO2
Number of subjects: 16

Group type: COMPARATOR
Intervention: Room Air (RA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Mask O2
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nasal O2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 16
Study: 16342925

Group type: EXPERIMENTAL
Intervention: Imatinib treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon-alpha treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated imatinib treatment (80% favorable survival times)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated imatinib treatment (65% favorable survival times)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulated imatinib treatment (50% favorable survival times)
Number of subjects: 0
Study: 12083753

Group type: EXPERIMENTAL
Intervention: Counselors‐CARE (C‐CAST)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Coping and Support Training (CAST)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 341
Study: 9649993

Group type: EXPERIMENTAL
Intervention: Minimal-flow anaesthesia (0.5 L min-1 fresh gas inflow)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Higher-flow anaesthesia (3 L min-1 fresh gas flow)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Desorption of adsorbed desflurane
Number of subjects: 13
Study: 7655967

Group type: EXPERIMENTAL
Intervention: Closed technique
Number of subjects: 95
Study: 2570043

Group type: EXPERIMENTAL
Intervention: Cardiologist provided with ejection fraction results
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ejection fraction results withheld from cardiologist
Number of subjects: 60
Study: 1028636

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 4

Group type: COMPARATOR
Intervention: Beta-methyl-digoxin
Number of subjects: 4
Study: 31100199

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination of aerobic and resistance exercise
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 27597129

Group type: EXPERIMENTAL
Intervention: eCHECKUP TO GO for High School
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 26357907

Group type: EXPERIMENTAL
Intervention: Internet-based healthy relationships video groups (HR-VG) delivered at home
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Internet-based healthy relationships video groups (HR-VG) delivered at community-based organizations (CBOs)
Number of subjects: 21
Study: 23123375

Group type: EXPERIMENTAL
Intervention: 10 mg extended release oxybutynin daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21515120

Group type: EXPERIMENTAL
Intervention: Small food-item size (candies cut in two)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Large food-item size (whole candies)
Number of subjects: 33
Study: 19030986

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 0
Study: 16247504

Group type: EXPERIMENTAL
Intervention: Ghrelin (3.6 nmol/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study: 14685866

Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 29

Group type: COMPARATOR
Intervention: Propelling surface size
Number of subjects: 29
Study: 10868824

Group type: EXPERIMENTAL
Intervention: HOE 901
Number of subjects: 333

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 333
Study: 9195242

Group type: EXPERIMENTAL
Intervention: Continuous autologous transfusion system (CATS)
Number of subjects: 10
Study: 1363204

Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser
Number of subjects: 50

Group type: COMPARATOR
Intervention: Trichloroacetic acid (TCA)
Number of subjects: 50
Study: 4029473

Group type: EXPERIMENTAL
Intervention: Electronic fetal monitoring (EFM)
Number of subjects: 655

Group type: COMPARATOR
Intervention: Auscultation (AUS)
Number of subjects: 655
Study: 2454373

Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: All medications
Number of subjects: 13
Study: 31310186

Group type: EXPERIMENTAL
Intervention: Involvement by family in care and discharge planning (contacting family members, communicating about the patient's health, and discharge plan)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Family phone calls and/or visits with patients, attendance at family therapy sessions, communication with inpatient staff about services available to families
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Inpatient staff contacting a family member
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Attendance at outpatient appointments
Number of subjects: 179
Study: 28337872

Group type: EXPERIMENTAL
Intervention: 10 mg ropivacaine (0.50%)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 12 mg ropivacaine (0.50%)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 14 mg ropivacaine (0.50%)
Number of subjects: 180
Study: 26159013

Group type: EXPERIMENTAL
Intervention: Peitu Shengjin Recipe (PSR), one dose per day
Number of subjects: 62

Group type: COMPARATOR
Intervention: Seretide (50/500 µg), twice per day
Number of subjects: 62
Study: 23200261

Group type: EXPERIMENTAL
Intervention: Tomato product (TP) consumption - one serving per day for 3 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tomato product (TP) consumption
Number of subjects: 36
Study: 21168923

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine with 1:200,000 epinephrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 1:200,000 epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study: 18048590

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 9
Study: 16501800

Group type: EXPERIMENTAL
Intervention: Preoperative intra-aortic balloon (IAB)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control group (surgery without circulatory assistance)
Number of subjects: 239
Study: 12548303

Group type: EXPERIMENTAL
Intervention: Enteral diet supplemented with arginine and dietary fibre (group I, n=18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous enteral formula (group II, n=18)
Number of subjects: 36
Study: 10894991

Group type: EXPERIMENTAL
Intervention: L‐dopa + lisuride
Number of subjects: 82

Group type: COMPARATOR
Intervention: L‐dopa alone
Number of subjects: 82
Study: 8936782

Group type: EXPERIMENTAL
Intervention: Omnipaque 300
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Omnipaque 240
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Omnipaque 180
Number of subjects: 110

Group type: COMPARATOR
Intervention: Diagnostic lumbar puncture
Number of subjects: 110
Study: 1402720

Group type: EXPERIMENTAL
Intervention: Response-stimulus intervals (RSI) of 500 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response-stimulus intervals (RSI) of 4,000 ms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Equal RSI and preceding RSI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blocked RSI and preceding RSI
Number of subjects: 0
Study: 4059296

Group type: EXPERIMENTAL
Intervention: 1 g triletide
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1.5 g triletide
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 2 g triletide
Number of subjects: 45

Group type: COMPARATOR
Intervention: Dose correlation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 45
Study: 30872064

Group type: EXPERIMENTAL
Intervention: BIAsp 30 TID
Number of subjects: 437

Group type: COMPARATOR
Intervention: BIAsp 30 BID
Number of subjects: 437
Study: 29945918

Group type: EXPERIMENTAL
Intervention: Risankizumab 18 mg
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Risankizumab 90 mg
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Risankizumab 180 mg
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 27792133

Group type: EXPERIMENTAL
Intervention: Walnut consumption
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 25006678

Group type: EXPERIMENTAL
Intervention: Ergocalciferol (50,000 IU weekly for one month followed by 50,000 IU monthly)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 22643537

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (400 mg/day for 36 months)
Number of subjects: 397

Group type: COMPARATOR
Intervention: Imatinib mesylate (400 mg/day for 12 months)
Number of subjects: 397
Study: 20391952

Group type: EXPERIMENTAL
Intervention: Octatropine plus diazepam (Valpinax) 40 mg/2.5 mg twice daily for 6 weeks
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 186
Study: 18272290

Group type: EXPERIMENTAL
Intervention: Nicotine (Nicorette 2 mg gum)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15721731

Group type: EXPERIMENTAL
Intervention: 500‐mg paracetamol + 75‐mg caffeine
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: 500‐mg paracetamol + 125‐mg caffeine
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 12099151

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 15
Study: 9861379

Group type: EXPERIMENTAL
Intervention: Chloroquine syrup (25 mg/kg)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Pyrimethamine/sulfadoxine
Number of subjects: 117
Study: 7898741

Group type: EXPERIMENTAL
Intervention: Conventional antiepileptic drugs (monotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polypharmacy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New antiepileptic agents
Number of subjects: 0
Study: 2146130

Group type: EXPERIMENTAL
Intervention: Etodolac (200 to 300 mg b.i.d. or 200 mg t.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etodolac (200 mg b.i.d.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etodolac (50 to 200 mg b.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen (250 to 375 mg b.i.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 374176

Group type: EXPERIMENTAL
Intervention: Motilin infusion (0.34 pmol/kg/min for 60 min, followed by 0.68 pmol/kg/min for 60 min)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Motilin infusion (high dose)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Motilin infusion (low dose)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Motilin infusion
Number of subjects: 5
Study: 29214826

Group type: EXPERIMENTAL
Intervention: Sedentary intervention (eliminate all exercise and minimize steps to ≤5000 steps/day for 1 week)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Normal physical activity (control group continued normal PA levels for 1 week)
Number of subjects: 33
Study: 26631103

Group type: EXPERIMENTAL
Intervention: 150-mg Artemisia annua extract (ART) twice daily (BD)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo BD
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 300-mg Artemisia annua extract (ART) twice daily (BD)
Number of subjects: 42
Study: 23611363

Group type: EXPERIMENTAL
Intervention: Individual daily pain treatment with acetaminophen, extended release morphine, buprenorphine transdermal patch, and/or pregabaline for 8 weeks
Number of subjects: 352

Group type: COMPARATOR
Intervention: Usual treatment and care
Number of subjects: 352
Study: 22258482

Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 0
Study: 19931345

Group type: EXPERIMENTAL
Intervention: Mandibular-implant overdentures
Number of subjects: 173

Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 173
Study: 17373915

Group type: EXPERIMENTAL
Intervention: Rifaximin (1200 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 16371674

Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended release (Adderall XR)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Atomoxetine (Strattera)
Number of subjects: 203
Study: 12214785

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural prevention session during hospitalization
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural programme with 5-8 weekly home-visits
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 258
Study: 9748032

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl
Number of subjects: 42
Study: 7920454

Group type: EXPERIMENTAL
Intervention: Carbenoxolone (300 mg/day for 5 days) in normal subjects
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Carbenoxolone (300 mg/day for 5 days) in patients with renal disease
Number of subjects: 13
Study: 2838979

Group type: EXPERIMENTAL
Intervention: Propranolol (75-100 mg/d)
Number of subjects: 18
Study: 30096440

Group type: EXPERIMENTAL
Intervention: Volunteer-provided palliative care services for people with cancer
Number of subjects: 157

Group type: COMPARATOR
Intervention: Volunteer-provided palliative care services for people without cancer
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Quality of life physical domain
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Quality of life environmental domain
Number of subjects: 157
Study: 26069034

Group type: EXPERIMENTAL
Intervention: Lower nicotine metabolite ratio (NMR <0.31)
Number of subjects: 1155

Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 1155

Group type: COMPARATOR
Intervention: Varenicline
Number of subjects: 1155
Study: 25261324

Group type: EXPERIMENTAL
Intervention: Pedometer-based programme
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard programme of physical activity encouragement
Number of subjects: 102
Study: 23359236

Group type: EXPERIMENTAL
Intervention: Polyethylene plastic drape
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional cotton drape
Number of subjects: 60
Study: 20800244

Group type: EXPERIMENTAL
Intervention: Histidine-tryptophan-ketoglutarate (HTK)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 80
Study: 18485612

Group type: EXPERIMENTAL
Intervention: Parent Skills with Behavioral Couples Therapy (PSBCT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Behavioral Couples Therapy (BCT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Individual-Based Treatment (IBT)
Number of subjects: 30
Study: 16825135

Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 21

Group type: COMPARATOR
Intervention: isotonic saline
Number of subjects: 21

Group type: COMPARATOR
Intervention: hydroxyethyl starch (HES)
Number of subjects: 21
Study: 12931755

Group type: EXPERIMENTAL
Intervention: Saliva incubation test
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hydrogen sulphide (H2S) measurement devices
Number of subjects: 8

Group type: COMPARATOR
Intervention: Organoleptic ratings
Number of subjects: 8
Study: 10828704

Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 33

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 33
Study: 9124658

Group type: EXPERIMENTAL
Intervention: ASA grade <= 2 and cardiac risk index group I (score 0-5 points)
Number of subjects: 16227

Group type: EXPERIMENTAL
Intervention: ASA grade = 4 and cardiac risk index group >= 3 (score > 13 points)
Number of subjects: 16227

Group type: EXPERIMENTAL
Intervention: ASA grade and cardiac risk index combined
Number of subjects: 16227
Study: 7518763

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 10 mg/kg twice daily for 10 days
Number of subjects: 74

Group type: COMPARATOR
Intervention: Cefaclor 10 mg/kg twice daily for 10 days
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil
Number of subjects: 74

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 74
Study: 2972165

Group type: EXPERIMENTAL
Intervention: remoxipride (75‐375 mg daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: thioridazine (150‐750 mg daily)
Number of subjects: 61
Study: 31585495

Group type: EXPERIMENTAL
Intervention: Transanal irrigation (TAI)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 23
Study: 30391300

Group type: EXPERIMENTAL
Intervention: Biomarker feedback intervention (n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Contact control usual care condition (n=30)
Number of subjects: 60
Study: 28288601

Group type: EXPERIMENTAL
Intervention: Multimodal behavioral intervention (MBI) treatment including telephone counseling, nicotine replacement therapy, mobile app support, multimedia text messages about TSE and smoking cessation.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Attention control intervention including nutrition-focused telephone counseling, mobile app, multimedia text messages about improving nutrition, and referral to state smoking cessation quitline.
Number of subjects: 100
Study: 24837362

Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 20 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/BZA 20 mg
Number of subjects: 4

Group type: COMPARATOR
Intervention: CE/BZA (both doses)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: CE/BZA (higher dose)
Number of subjects: 4
Study: 22852560

Group type: EXPERIMENTAL
Intervention: Genetic counseling regarding risk for DM
Number of subjects: 600

Group type: COMPARATOR
Intervention: Conventional risk counseling for DM with eye disease counseling
Number of subjects: 600
Study: 20164800

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT‐A) injection
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Both groups (BoNT‐A and placebo)
Number of subjects: 19
Study: 17907111

Group type: EXPERIMENTAL
Intervention: tesaglitazar 0.5 mg
Number of subjects: 392

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 392
Study: 16254580

Group type: EXPERIMENTAL
Intervention: Dietary intake assessment and biochemical measures of vitamin status
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Correlation of plasma vitamin A and serum zinc
Number of subjects: 387
Study: 11929492

Group type: EXPERIMENTAL
Intervention: Triamcinolone (400 microg)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Montelukast (5 or 10 mg)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Formoterol (24 microg)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 10422937

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5 MAC)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.0 MAC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol (control group)
Number of subjects: 20
Study: 7498593

Group type: EXPERIMENTAL
Intervention: Mirage bond/Silux
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Tenure/Opalux
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Tripton/Opalux
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Scotchbond 2/Silux
Number of subjects: 81
Study: 2572181

Group type: EXPERIMENTAL
Intervention: Topical levocabastine applied twice daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sodium cromoglycate applied four times a day
Number of subjects: 37
Study: 1086728

Group type: EXPERIMENTAL
Intervention: Schwarz live, further attenuated measles virus vaccine at full dose (0.5 ml)
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: Schwarz live, further attenuated measles virus vaccine at reduced doses (40%, 60%, or 80%)
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: Schwarz live, further attenuated measles virus vaccine at reduced volume below 0.5 ml
Number of subjects: 967

Group type: EXPERIMENTAL
Intervention: Schwarz live, further attenuated measles virus vaccine in children below 12 months of age
Number of subjects: 967
Study: 31226790

Group type: EXPERIMENTAL
Intervention: IER+MED
Number of subjects: 60

Group type: COMPARATOR
Intervention: DASH
Number of subjects: 60
Study: 28376103

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 25788230

Group type: EXPERIMENTAL
Intervention: CT coronary angiography (CTCA)
Number of subjects: 4146

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 4146
Study: 24261687

Group type: EXPERIMENTAL
Intervention: MetSizeR methodology for sample size estimation
Number of subjects: 0
Study: 21985174

Group type: EXPERIMENTAL
Intervention: Baseline imaging after completion of 5-7 months of anticoagulant therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: No baseline imaging after completion of 5-7 months of anticoagulant therapy
Number of subjects: 121
Study: 20415155

Group type: EXPERIMENTAL
Intervention: Knowledge of strength test results
Number of subjects: 32

Group type: COMPARATOR
Intervention: No knowledge of strength test results
Number of subjects: 32
Study: 16481815

Group type: EXPERIMENTAL
Intervention: Nonabsorbable packing (NAP) in the middle meatus for 5 days
Number of subjects: 61

Group type: COMPARATOR
Intervention: Saline irrigations postoperatively (Control)
Number of subjects: 61
Study: 15630988

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemo-radiotherapy in patients with resectable tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination treatments with newer chemotherapy agents and optimal radiotherapy protocols
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palliative treatment strategies
Number of subjects: 0
Study: 10652925

Group type: EXPERIMENTAL
Intervention: Dynamic contrast‐enhanced whole‐abdomen axial images
Number of subjects: 32